This highlights the need for further research into the molecular mechanisms driving IBD-related CRC (IBD-CRC) and the identification of novel therapeutic targets, with emerging evidence pointing to the cGAS-STING pathway as a key player in both human and experimental IBD models [13]. This evidence concerns the gene CGAS and colorectal carcinoma.